TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) had its target price cut by analysts at Canaccord Genuity Group from $12.00 to $11.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Canaccord Genuity Group's target price points to a potential upside of 179.90% from the stock's current price.
Several other equities research analysts have also issued reports on the company. Roth Mkm began coverage on TriSalus Life Sciences in a report on Monday. They set a "buy" rating and a $11.00 price target for the company. Northland Securities started coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They issued an "outperform" rating and a $12.50 price target for the company. Roth Capital raised TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a research note on Monday, September 16th. They issued an "outperform" rating and a $10.00 target price on the stock. Finally, Northland Capmk raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, TriSalus Life Sciences has an average rating of "Buy" and a consensus target price of $12.08.
Check Out Our Latest Report on TriSalus Life Sciences
TriSalus Life Sciences Price Performance
TriSalus Life Sciences stock traded down $0.08 during trading hours on Friday, hitting $3.93. The company had a trading volume of 27,024 shares, compared to its average volume of 38,374. TriSalus Life Sciences has a fifty-two week low of $3.32 and a fifty-two week high of $10.42. The firm has a market capitalization of $119.83 million, a P/E ratio of -1.57 and a beta of 0.49. The firm's fifty day moving average is $4.35 and its 200-day moving average is $5.84.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $7.36 million during the quarter. Analysts anticipate that TriSalus Life Sciences will post -1.5 earnings per share for the current year.
Insider Buying and Selling at TriSalus Life Sciences
In other TriSalus Life Sciences news, CEO Mary T. Szela acquired 7,520 shares of the company's stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. This represents a 2.03 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 32.80% of the company's stock.
Institutional Investors Weigh In On TriSalus Life Sciences
A number of institutional investors have recently added to or reduced their stakes in the stock. Walleye Capital LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth approximately $66,000. MSD Partners L.P. bought a new position in shares of TriSalus Life Sciences during the third quarter valued at $184,000. Wolverine Asset Management LLC bought a new stake in shares of TriSalus Life Sciences in the 2nd quarter worth about $240,000. Highbridge Capital Management LLC acquired a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth about $1,184,000. Finally, Duquesne Family Office LLC lifted its holdings in TriSalus Life Sciences by 35.1% during the 2nd quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock valued at $2,357,000 after purchasing an additional 110,966 shares during the last quarter. 2.58% of the stock is owned by institutional investors and hedge funds.
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Recommended Stories
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
